<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2027">
  <stage>Registered</stage>
  <submitdate>29/06/2008</submitdate>
  <approvaldate>29/06/2008</approvaldate>
  <nctid>NCT00707603</nctid>
  <trial_identification>
    <studytitle>Chronic Hepatitis C and Insulin Resistance</studytitle>
    <scientifictitle>Understanding the Relationship Between Insulin Resistance and Chronic Hepatitis C Infection</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>H04/126</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis C</healthcondition>
    <healthcondition>Insulin Resistance</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Hepatitis C subjects - Due to start therapy for Hepatitis C

Controls - Healthy males

</interventions>
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Insulin Resistance by euglycaemic hyperinsulinaemic clamp Liver fat, abdominal fat and muscle fat measures</outcome>
      <timepoint>2 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>insulin resistance post treatment of Hep C</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Caucasian male

          -  Age: 25-55 years

          -  Chronic Hepatitis C (PCR positive) and fibrosis = F2 (if liver biopsy done)

          -  Genotypes 1 or 3

          -  Due to commence antiviral therapy

          -  BMI &lt; 30</inclusivecriteria>
    <inclusiveminage>25</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Cirrhosis or F3 fibrosis on liver biopsy (if done)

          -  &gt; 20 g ETOH per day

          -  Type 2 Diabetes (need an OGTT if fasting BGL&gt; 5.7)

          -  Concurrent HIV

          -  Other cause of liver disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration>Cross-sectional</duration>
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>50</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Garvan Institute Of Medical Research - Sydney</hospital>
    <hospital>Storr Liver Unit - Sydney</hospital>
    <postcode>2010 - Sydney</postcode>
    <postcode>2145 - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Garvan Institute of Medical Research</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Chronic hepatitis C (CHC) is among the commonest chronic infectious disease in Australia with
      &gt;200,000 exposed persons. Amongst non-infectious chronic conditions- Type 2 diabetes, obesity
      and heart disease are extremely common. This study will examine the relationship between
      insulin resistance, fat deposition in the liver, muscle and abdomen, and liver injury due to
      CHC</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00707603</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Donald Chisholm, MBBS, FRACP</name>
      <address>Garvan Institute of Medical Research</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>